Drug Information

Drug General Information
Drug ID
D0DO5J
Former ID
DIB016337
Drug Name
MDAM (y-methylene-10-deazaaminopterin)
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [527024]
Company
BioNumerik Pharmaceuticals
Target and Pathway
Target(s) DHFR Target Info Inhibitor [533440]
KEGG Pathway One carbon pool by folate
Folate biosynthesis
Metabolic pathways
PANTHER Pathway Tetrahydrofolate biosynthesis
Formyltetrahydroformate biosynthesis
Pathway Interaction Database E2F transcription factor network
PathWhiz Pathway Folate Metabolism
Pterine Biosynthesis
Reactome E2F mediated regulation of DNA replication
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
Metabolism of folate and pterines
G1/S-Specific Transcription
WikiPathways Nucleotide Metabolism
Trans-sulfuration and one carbon metabolism
Retinoblastoma (RB) in Cancer
One Carbon Metabolism
Metabolism of water-soluble vitamins and cofactors
Metabolism of nitric oxide
Folate Metabolism
Fluoropyrimidine Activity
References
Ref 527024Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. Cancer Chemother Pharmacol. 2004 May;53(5):370-6. Epub 2003 Dec 18.
Ref 533440Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.